What is going on with DaVita stock?
DaVita Inc. has experienced substantial growth recently, with its stock price rising significantly from approximately $210 in mid-June to close at $240.09 on July 31, 2026. This reflects a notable 14% increase over the period. With a market capitalization exceeding $15 billion and an earnings per share of $10.77, the stock has been trading near its 52-week high of $244.49. The positive momentum has been consistent throughout July, positioning the company strongly within the healthcare services sector on the NYSE as it enters the new month.
Related FAQs
DaVita (DVA) currently holds a consensus "Hold" rating among analysts. While 33% of analysts recommend a "Strong Buy," 50% suggest "Holding," and 17% advise "Selling.
The ticker symbol DVA represents DaVita Inc., a major Fortune 500 healthcare services company publicly traded on the New York Stock Exchange that specializes in providing kidney dialysis services.
DaVita Inc., traded on the New York Stock Exchange under the ticker symbol DVA, is a leading American healthcare provider that specializes in kidney care and the treatment of patients with chronic kidney disease.
The Chief Executive Officer of Dollar Tree Inc. is compensated through a structured executive remuneration plan outlined in annual proxy filings. Total annual compensation for the chief executive officer typically ranges between 7.6 million and 9.
DaVita Inc., a leading provider of kidney dialysis services in outpatient clinics and hospitals across the United States and international markets, is regularly processed through the Zacks quantitative evaluation model.
As of July 2026, there is significant debate regarding the valuation of DaVita (DVA) stock.
Yes, "Dx" is a standard medical abbreviation used by healthcare professionals as shorthand for "diagnosis.
Warren Buffett does not hold shares of Diageo plc (trading under the ticker DEO) within Berkshire Hathaway's investment portfolio.
DaVita Inc.
As of mid-2026, analyst consensus on DaVita (DVA) is mixed and suggests a cautious approach. Recent ratings indicate that 33% of analysts recommend a "Strong Buy," while 50% suggest "Holding" the stock, and 17% advise "Selling".
DaVita Inc., a major provider of kidney dialysis services, has been embroiled in significant healthcare fraud investigations, whistleblower lawsuits, and federal settlements involving allegations of illegal physician kickbacks.
DaVita has undergone several rounds of layoffs and job cuts over the past few years, particularly between 2022 and 2024, as part of a multi-year restructuring and cost-cutting initiative.
DaVita Inc. (DVA) carries a consensus Hold to Buy rating among healthcare service analysts, with average 12-month price targets clustering around $216.50 to $217.33 per share, while high institutional projections reach up to $270.00.